Franklin Street Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Franklin Street Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,142	Closed	-$41K	–	160
2019 Q4	$41K	Buy	3,142 +2,000	+175%	+$18.5K	﹤0.01%	152
2019 Q3	$12K	Hold	1,142	–	–	﹤0.01%	157
2019 Q2	$19K	Hold	1,142	–	–	﹤0.01%	159
2019 Q1	$38K	Sell	1,142 -4,000	-78%	-$134K	0.01%	156
2018 Q4	$150K	Buy	5,142 +130	+3%	+$5.77K	0.02%	138
2018 Q3	$309K	Sell	5,012 -43	-0.9%	-$2.91K	0.04%	127
2018 Q2	$373K	Buy	5,055 +86	+2%	+$6.7K	0.05%	117
2018 Q1	$326K	Buy	4,969 +140	+3%	+$10.6K	0.05%	126
2017 Q4	$406K	Buy	4,829 +3,600	+293%	+$353K	0.06%	115
2017 Q3	$142K	Buy	+1,229	New	+$129K	0.02%	150
2017 Q2	–	Sell	-2,559	Closed	-$316K	–	163
2017 Q1	$316K	Buy	+2,559	New	+$335K	0.06%	131

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Franklin Street Advisors's BLCM Position: Q1 2020 in Review

Franklin Street Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2020, closing a stake of 3,142 shares — an estimated $41K sold.

Franklin Street Advisors first reported a position in BLCM in Q1 2017 and held it in 11 quarters. The position peaked at $406K in Q4 2017. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2020.

Franklin Street Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Franklin Street Advisors sold 3,142 Bellicum Pharmaceuticals, Inc. shares in Q1 2020, an estimated $41K.
Franklin Street Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2017 and held it in 11 quarters.
Franklin Street Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $406K in Q4 2017.
29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2020.

Based on Franklin Street Advisors's 13F filing for Q1 2020, filed 16 Apr 2020.